$11.73
+0.01 (+0.09%)
Open$11.64
Previous Close$11.72
Day High$11.84
Day Low$11.56
52W High$13.90
52W Low$7.36
Volume—
Avg Volume1.74M
Market Cap1.01B
P/E Ratio—
EPS$-3.36
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
+291.5% upside
Current
$11.73
$11.73
Target
$45.92
$45.92
$25.11
$45.92 avg
$52.51
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 65.52M | 146.41M | 142.51M |
| Net Income | -270,542,124 | 21.31M | 25.50M |
| Profit Margin | -413.0% | 14.6% | 17.9% |
| EBITDA | -293,771,090 | 41.90M | 41.44M |
| Free Cash Flow | — | 24.20M | 22.28M |
| Rev Growth | — | -6.0% | +22.0% |
| Debt/Equity | 0.06 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |